BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 15692609)

  • 1. Replicating retroviral vectors mediating continuous production and secretion of therapeutic gene products from cancer cells.
    Finger C; Sun Y; Sanz L; Alvarez-Vallina L; Buchholz CJ; Cichutek K
    Cancer Gene Ther; 2005 May; 12(5):464-74. PubMed ID: 15692609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor cell-specific gene transfer with retroviral vectors displaying single-chain antibody.
    Tang Y; Li Y; Qian G
    Chin Med J (Engl); 2002 Jul; 115(7):1064-9. PubMed ID: 12150744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted gene transfer to lymphocytes using murine leukaemia virus vectors pseudotyped with spleen necrosis virus envelope proteins.
    Engelstädter M; Buchholz CJ; Bobkova M; Steidl S; Merget-Millitzer H; Willemsen RA; Stitz J; Cichutek K
    Gene Ther; 2001 Aug; 8(15):1202-6. PubMed ID: 11509952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retroviral vectors for gene therapy of AIDS and cancer.
    Chang LJ; He J
    Curr Opin Mol Ther; 2001 Oct; 3(5):468-75. PubMed ID: 11699891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of chimeric envelope proteins in helper cell lines and integration into Moloney murine leukemia virus particles.
    Schnierle BS; Moritz D; Jeschke M; Groner B
    Gene Ther; 1996 Apr; 3(4):334-42. PubMed ID: 8732165
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved gene transfer selectivity to hepatocarcinoma cells by retrovirus vector displaying single-chain variable fragment antibody against c-Met.
    Nguyen TH; Loux N; Dagher I; Vons C; Carey K; Briand P; Hadchouel M; Franco D; Jouanneau J; Schwall R; Weber A
    Cancer Gene Ther; 2003 Nov; 10(11):840-9. PubMed ID: 14605670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Process validation and clinical evaluation of a protocol to generate gene-modified T lymphocytes for imunogene therapy for metastatic renal cell carcinoma: GMP-controlled transduction and expansion of patient's T lymphocytes using a carboxy anhydrase IX-specific scFv transgene.
    Lamers CH; van Elzakker P; Langeveld SC; Sleijfer S; Gratama JW
    Cytotherapy; 2006; 8(6):542-53. PubMed ID: 17148030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo evaluation of an EIAV vector for the systemic genetic delivery of therapeutic antibodies.
    Lamikanra A; Myers KA; Ferris N; Mitrophanous KA; Carroll MW
    Gene Ther; 2005 Jun; 12(12):988-98. PubMed ID: 15772687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reconstituting retroviral (ReCon) vectors facilitating delivery of cytotoxic genes in cancer gene therapy approaches.
    Brandtner EM; Kodajova P; Hlavaty J; Jandl G; Tabotta W; Salmons B; Günzburg WH; Hohenadl C
    J Gene Med; 2008 Feb; 10(2):113-22. PubMed ID: 18076132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
    Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
    Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of a semi-replicative gene delivery system allowing propagation of complementary defective retroviral vectors.
    Trajcevski S; Solly SK; Frisén C; Trenado A; Cosset FL; Klatzmann D
    J Gene Med; 2005 Mar; 7(3):276-87. PubMed ID: 15515136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel human suspension culture packaging cell line for production of high-titre retroviral vectors.
    Chan LM; Coutelle C; Themis M
    Gene Ther; 2001 May; 8(9):697-703. PubMed ID: 11406764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of adenoviral vectors through a bispecific single-chain antibody.
    Haisma HJ; Grill J; Curiel DT; Hoogeland S; van Beusechem VW; Pinedo HM; Gerritsen WR
    Cancer Gene Ther; 2000 Jun; 7(6):901-4. PubMed ID: 10880021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Targeted inhibition of rabies virus replication in vitro by single chain antibody domain mediated vector expression shRNA delivery].
    Yang R; Cui Y; Yang S; Wang C; Shan H; Wang H; Xia X
    Wei Sheng Wu Xue Bao; 2010 Feb; 50(2):256-62. PubMed ID: 20387470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Murine leukemia virus (MLV) replication monitored with fluorescent proteins.
    Sliva K; Erlwein O; Bittner A; Schnierle BS
    Virol J; 2004 Dec; 1():14. PubMed ID: 15610559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly efficient gene delivery for bladder cancers by intravesically administered replication-competent retroviral vectors.
    Kikuchi E; Menendez S; Ozu C; Ohori M; Cordon-Cardo C; Logg CR; Kasahara N; Bochner BH
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4511-8. PubMed ID: 17671137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RD114-pseudotyped retroviral vectors kill cancer cells by syncytium formation and enhance the cytotoxic effect of the TK/GCV gene therapy strategy.
    Germain E; Roullin VG; Qiao J; de Campos Lima PO; Caruso M
    J Gene Med; 2005 Apr; 7(4):389-97. PubMed ID: 15619289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of a retroviral vector production system with the minimum possibility of a homologous recombination.
    Yu SS; Han E; Hong Y; Lee JT; Kim S; Kim S
    Gene Ther; 2003 Apr; 10(8):706-11. PubMed ID: 12692599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
    Li X; Stuckert P; Bosch I; Marks JD; Marasco WA
    Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.